Research
AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events
The Brief
- Pelacarsen, a monthly antisense oligonucleotide, lowers lipoprotein(a) levels in adults with preexisting cardiovascular disease.
- The drug does not reduce the occurrence of major adverse cardiovascular events in the same group.
- The findings were published online on Nov. 7 and reported by the American Heart Association.
Why it matters
Lowering lipoprotein(a) alone did not translate into fewer major cardiovascular events in this population, which bears on whether this biomarker is a valid treatment target.
Who’s affected
- cardiologists and clinical researchers working on lipoprotein(a) therapies
- patients with established cardiovascular disease
- #lipoprotein(a)
- #cardiovascular
- #pelacarsen
- #antisense oligonucleotide
- #clinical trial
For adults with preexisting cardiovascular disease, pelacarsen, an antisense oligonucleotide administered monthly, lowers lipoprotein(a) levels but does not reduce the occurrence of major adverse cardiovascular events, according to a study published online Nov. 7 in the New…